At several times of life it happens that any distinct organization or entity being engaged thoroughly towards the process of investigative studies or scientific researches due to the sudden and extreme financial constraints get forced to close down many of its ongoing research studies but if at that opportune moment some another distinct organization comes forward with a promise of incessant flow of money, there takes place a certain rejuvenation through the dried cells of the Company. The same has happened with the cash strapped BrainStorm Cell Therapeutics, at Petach Tikvah in Israel who has announced here today that it shall be able in due process to raise up to $5 million from the well-known ACCBT Corporation. It has also been stated in this regard, that in the recently concluded SEC filings the company reported of the possession of the amount of $154,000 in cash while there has also been an amount of more than $3 million in liabilities together with the investor loans.

BrainStorm is one of the premiere companies that is thoroughly determined and thus dedicated its entire energy in the development of the stem cell technologies with the sole intention of providing well-researched treatments for the specific neurodegenerative diseases that are incurable in the contemporary age. For the further escalation of its course of operation the company has its core attention on the saga of development of the adult stem cells that are obtained from the respective patient's bone marrow for the thorough treatment of diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) and Multiple Sclerosis (MS). While asking the responsible echelons about the imperative role of the stem cells it is learnt that the stem cells are utilized as part of a general process towards the creation of new brain-like cells but in good physical shape or supporting the diseased cells. There remains a general anticipation that the patients who get treated with the Company's NurOwn™ therapeutic cells are able to enjoy a speedy recovery in conjunction with much enhanced quality of life BrainStorm's therapy has the potential to cure underlying pathology, rather than simply treat symptoms.

As has been revealed form the Company, it has come to the knowledge that being a Company under the tutelage of Chaim Lebovits, the fresh investments by the ACCBT will be made in installments, providing needed working capital.

While speaking on the occasion the chief operating officer, Yoram Drucker said,   "The new funding will help us accelerate our safety trials for Parkinson's disease as well as advance our other adult stem cell therapy programs aimed at ALS, multiple sclerosis and other neurodegenerative disorders."